

Technology Appraisal Committee D Interests Register

Topic: Cabozantinib for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine [ID4046]

Publication Date: 01/11/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Jonathan Wadsley	Clinical expert	Direct & indirect financial	Professor Wadsley declared financial interests as his institution has received payments for him to provide advice and act as speaker for Eisai, Ipsen, Bayer, Roche, AstraZeneca, Sanofi-Genzyme, Novartis (AAA). He has also received research funding from AstraZeneca and Sanofi-Genzyme.	04.08.2022	It was agreed his declarations would not prevent Professor Wadsley from providing expert advice to the committee